No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACAD240816C21000
- 0.55
- +0.05+10.00%
15min DelayClose Jul 22 16:00 ET
0.55High0.50Low
0.50Open0.50Pre Close17 Volume250 Open Interest21.00Strike Price905.00Turnover79.71%IV18.86%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.55Extrinsic Value100Contract SizeAmericanOptions Type0.2818Delta0.0887Gamma30.22Leverage Ratio-0.0261Theta0.0031Rho8.51Eff Leverage0.0161Vega
Intraday
- 5D
- Daily
News
Express News | Acadia Pharmaceuticals Announces Continued Improvements In RSBQ And CGI-I Scores With Long-Term DAYBUE Treatment In Phase 3 LAVENDER And LILAC Studies; DAYBUE Safety Profile Consistent With LAVENDER Trial Findings; Published Results Show Improved Rett...
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Acadia Pharmaceuticals (ACAD Quick QuoteACAD - Free Report) is a commercial-stage company focused on developing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
TD Cowen Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
TD Cowen analyst Ritu Baral maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 47.9%
TD Cowen Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Is Maintained at Overweight by Morgan Stanley
ACADIA Pharmaceuticals Is Maintained at Overweight by Morgan
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $28
Morgan Stanley analyst Jeffrey Hung maintains $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and adjusts the target price from $30 to $28.According to TipRanks data, the analyst has a success
Comments
» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte(INCY.US$
$BeiGene(BGNE.US$
$ACADIA Pharmaceuticals(ACAD.US$
$Madrigal Pharmaceuticals(MDGL.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Revolution Medicines(RVMD.US$
$Kymera Therapeutics(KYMR.US$
$AbCellera Biologics(ABCL.US$
$Bicycle Therapeutics(BCYC.US$
$Edgewise Therapeutics(EWTX.US$
$Immunocore(IMCR.US$
$Kodiak Sciences(KOD.US$
$Roivant Sciences(ROIV.US$
...
8
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
1
Several companies were in the spotlight due to various developments:
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
Oracle ( $Oracle(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $ACADIA Pharmaceuticals(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$Asana(ASAN.US$ Asana rep...
2
$ACADIA Pharmaceuticals(ACAD.US$ And where will the bottom be? Could it be a opportunity? Time will tell? Hehehe![]()
$ACADIA Pharmaceuticals(ACAD.US$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
Read more